<qa>  What is the name of the drug that targets the erbB receptor family?Prior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments 6 weeks for nitrosoureas or mitomycin; immunotherapy including Herceptin or other biologic therapy within 2 weeks prior to baseline disease assessments; hormone therapy including hormone replacement therapy within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol acetate to exclude the possibility of a hormone-withdrawal response; patients with untreated brain metastases. 